Brainsway (BWAY) Stock: Buy, Sell, or Hold?
BWAY - Brainsway Ltd. American Depositary Shares
$13.93
0.02 (0.14%)
▲
5d:
-4.0%
30d:
-16.08%
90d:
-5.17%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When BWAY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: BWAY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$24.67
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$15.32
9.1% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BWAY is currently trading at $13.93, which is considered oversold relative to its 30-day fair value range of $14.15 to $15.66. From a valuation perspective, the stock is trading at a discount (Forward PE: 27.5) compared to its historical average (45.6). Remarkably, the market is currently pricing in an annual earnings decline of 15.5% over the next few years. This pessimistic expectation contrasts with the company's recent 64.6% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $13.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BWAY scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.27 (+38.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BWAY is in a downtrend. The price is currently testing key support at $13.68. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: BWAY scores 60/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $19.27 (+38.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$14.15 -
$15.66
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
90.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 38.3% below Wall St target ($19.27)
- WARNING: Composite score 47/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$14.15 -
$15.66
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$13.68
Resistance Level
$14.78
Current Trend
Downtrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
27.49
Wall Street Target
$19.27
(+38.3%)
Revenue Growth (YoY)
35.4%
Earnings Growth (YoY)
64.6%
Profit Margin
15.6%
Valuation Discount vs History
-15.5% cheaper
PE vs Historical
27.5 vs 45.6
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-15.5%
(market-implied from PE analysis)
1-Year Target
$12.54
(-10%)
2-Year Target
$11.28
(-19%)
3-Year Target
$10.15
(-27%)
3-Yr Target (if PE normalizes)
(PE: 27→46)
$16.84
(+21%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 27.5, Growth: 65.2%)
$47.01
(+238%)
Base:
(SPY PE: 20.2, Growth: 65.2%)
$34.49
(+148%)
Bear:
(PE: 17.1, Growth: 65.2%)
$29.32
(+111%)
📈
Valuation based on Current Earnings
Forward PE: 19.08 | Forward EPS (Implied): $0.73
Bull Case
$16.82
(+21%)
Analyst growth 15.0%, PE expands to 20.0
Base Case
$13.93
(0%)
Market implied 0.0%, PE stable at 19.1
Bear Case
$10.66
(-24%)
Severe decline -15.0%, PE contracts to 17.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 27.5 to 45.6
Stabilization Target:
$23.11
(+65.9%)
PE Expansion Potential:
+65.9%
Share & Embed Analysis
Last updated: September 11, 2026 11:27 PM ET
Data refreshes hourly during market hours. Next update: 12:27 AM
Data refreshes hourly during market hours. Next update: 12:27 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BWAY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$63 | 49 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$105 | 52 HOLD |
|
EW
Edwards Lifesciences Corp |
HOLD
32 analysts |
$101 | 56 HOLD |
|
ABT
Abbott Laboratories |
STRONG BUY
27 analysts |
$120 | 41 HOLD |
|
PODD
Insulet Corporation |
STRONG BUY
24 analysts |
$172 | 41 HOLD |
